PMN Stock Overview
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ProMIS Neurosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.05 |
| 52 Week High | US$8.95 |
| 52 Week Low | US$0.95 |
| Beta | 0.71 |
| 1 Month Change | 12.64% |
| 3 Month Change | 3.54% |
| 1 Year Change | -69.81% |
| 3 Year Change | -77.22% |
| 5 Year Change | -81.92% |
| Change since IPO | -91.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| PMN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.2% | 1.5% | 1.2% |
| 1Y | -69.8% | 1.1% | 24.7% |
Return vs Industry: PMN underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: PMN underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| PMN volatility | |
|---|---|
| PMN Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PMN's share price has been volatile over the past 3 months.
Volatility Over Time: PMN's weekly volatility has decreased from 24% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 7 | Neil K. Warma | www.promisneurosciences.com |
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils.
ProMIS Neurosciences, Inc. Fundamentals Summary
| PMN fundamental statistics | |
|---|---|
| Market cap | US$37.96m |
| Earnings (TTM) | -US$13.21m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.9x
P/E RatioIs PMN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PMN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$7.88m |
| Gross Profit | -US$7.88m |
| Other Expenses | US$5.33m |
| Earnings | -US$13.21m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PMN perform over the long term?
See historical performance and comparison